Arias-Alpizar Gabriela, Koch Bjørn, Hamelmann Naomi M, Neustrup Malene A, Paulusse Jos M J, Jiskoot Wim, Kros Alexander, Bussmann Jeroen
Department of Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry (LIC), Leiden University, RA, Leiden, The Netherlands; Division of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR), Leiden University, RA, Leiden, The Netherlands.
Department of Molecular Cell Biology, Institute Biology Leiden (IBL), Leiden University, RA, Leiden, The Netherlands.
Nanomedicine. 2021 Jun;34:102395. doi: 10.1016/j.nano.2021.102395. Epub 2021 Apr 8.
Clearance of nanoparticles (NPs) after intravenous injection - mainly by the liver - is a critical barrier for the clinical translation of nanomaterials. Physicochemical properties of NPs are known to influence their distribution through cell-specific interactions; however, the molecular mechanisms responsible for liver cellular NP uptake are poorly understood. Liver sinusoidal endothelial cells and Kupffer cells are critical participants in this clearance process. Here we use a zebrafish model for liver-NP interaction to identify the endothelial scavenger receptor Stabilin-1 as a non-redundant receptor for the clearance of small anionic NPs. Furthermore, we show that physiologically, Stabilin-1 is required for the removal of bacterial lipopolysaccharide (LPS/endotoxin) from circulation and that Stabilin-1 cooperates with its homolog Stabilin-2 in the clearance of larger (~100 nm) anionic NPs. Our findings allow optimization of anionic nanomedicine biodistribution and targeting therapies that use Stabilin-1 and -2 for liver endothelium-specific delivery.
静脉注射后纳米颗粒(NPs)的清除——主要通过肝脏——是纳米材料临床转化的关键障碍。已知NPs的物理化学性质会通过细胞特异性相互作用影响其分布;然而,负责肝脏细胞摄取NP的分子机制却知之甚少。肝窦内皮细胞和库普弗细胞是这一清除过程的关键参与者。在这里,我们使用斑马鱼模型研究肝脏与NP的相互作用,以确定内皮清道夫受体Stabilin-1是清除小阴离子NP的非冗余受体。此外,我们还表明,在生理上,循环中细菌脂多糖(LPS/内毒素)的清除需要Stabilin-1,并且在清除较大(约100nm)阴离子NP时,Stabilin-1与其同源物Stabilin-2协同作用。我们的研究结果有助于优化阴离子纳米药物的生物分布,并实现利用Stabilin-1和-2进行肝脏内皮特异性递送的靶向治疗。